Search EVFM
Evofem Biosciences, Inc.
OTC · CIK 1618835
Last close0.01
Daily change+0.00 (14.29%)
10 Years gain-100.00%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
EVFM · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
52.2Momentum
15.7Acceleration
15.7Confidence
84.0Annual Revenue7
Quarterly Revenue22
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth6.0 / 25
Quality18.7 / 25
Capital Efficiency20.0 / 20
Balance Sheet4.9 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 1.1123 percentage points.
Share count reductionDiluted share count declined 97.7687%.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Operating margin compression · MEDIUMOperating margin compressed by 6.8579 percentage points.
Key Metrics
Revenue Growth TTM1.56%OK
Revenue CAGR 3Y6.23%OK
Gross Margin80.61%OK
Operating Margin-55.29%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-97.77%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $20.18M | $15.57M | $3.37M | -$1.99M | -$2.00M | 77.12% | 16.71% | -9.89% | n/a | 6.42B |
| 2025 FY Dec 31, 2024 | $19.36M | $15.53M | -$7.68M | -$3.89M | -$3.90M | 80.2% | -39.64% | -20.14% | n/a | 80M |
| 2024 FY Dec 31, 2023 | $18.22M | $11.71M | -$17.85M | -$8.97M | -$8.97M | 64.26% | -97.96% | -49.25% | n/a | 984.04M |
| 2023 FY Dec 31, 2022 | $16.84M | $12.42M | -$84.12M | -$70.41M | -$70.75M | 73.78% | -499.64% | -420.21% | n/a | 465,967 |
| 2022 FY Dec 31, 2021 | $8.24M | $4.19M | -$166.80M | -$146.67M | -$149.61M | 50.81% | -2,023.3% | -1,814.73% | n/a | 8.73M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $13.31M | sum latest 4 fiscal quarters Revenue | OK | 0001493152-26-038328, 0001493152-25-022275 |
| Revenue Growth TTM | 1.56% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-26-038328, 0001493152-25-022275 |
| Revenue CAGR 3Y | 6.23% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-009686 |
| Revenue CAGR 5Y | 114.35% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001493152-26-009686 |
| Gross Profit CAGR 3Y | 7.81% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-009686 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001493152-26-038328, 0001493152-25-022275 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 80.61% | Gross Profit / Revenue | OK | 0001493152-26-038328, 0001493152-25-022275 |
| Operating Margin | -55.29% | Operating Income / Revenue | OK | 0001493152-26-038328, 0001493152-25-022275 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001493152-26-038328 |
| Current Ratio | 0.07x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.79x | (Cash + Short-term Investments) / Total Debt | OK | 0001493152-26-038328 |
| Revenue per Diluted Share | $0.10 | Revenue / Diluted Shares | OK | 0001493152-26-038328, 0001493152-25-022275 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |